Mineralys Therapeutics, Inc. (MLYS) Misses Q2 EPS by 22c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q2 EPS of ($2.85), $0.22 worse than the analyst estimate of ($2.63).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• Evercore (EVR) 2K contracts of October 280 calls trade, share price down 1%
• UBS Mulls Merger With Foreign Bank - Semafor